SCHEDULE: Vanguard Reports 0% Stake in Voyager Therapeutics

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Voyager Therapeutics Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 5 to Schedule 13G for Voyager Therapeutics Inc. Common Stock.
• The filing indicates that The Vanguard Group now beneficially owns 0.00 shares, representing 0% of the class.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• In accordance with SEC Release No. 34-39538, certain subsidiaries or business divisions of Vanguard will now report beneficial ownership separately (on a disaggregated basis).
• These subsidiaries and business divisions will continue to pursue the same investment strategies as previously pursued by The Vanguard Group, Inc.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for Voyager Therapeutics Inc. as it primarily reflects an internal administrative change in reporting for The Vanguard Group, rather than a fundamental shift in investment strategy or a divestment by Vanguard's underlying funds.

Positives

• The internal realignment ensures that Vanguard's subsidiaries will continue to pursue the same investment strategies, suggesting ongoing investment interest from the broader Vanguard ecosystem in companies like Voyager Therapeutics Inc.

Negatives

• The immediate public record shows The Vanguard Group, Inc. (the parent entity) no longer holding a beneficial ownership stake, which could be misinterpreted by some investors as a full divestment by the entire Vanguard organization if the nuance of disaggregated reporting is missed.

Future Outlook

NA

Management Comments

• The Vanguard Group, Inc. went through an internal realignment on January 12, 2026.
• Certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538.
• These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that this filing reflects an administrative change within The Vanguard Group's reporting structure rather than a strategic divestment from Voyager Therapeutics Inc. While the parent entity no longer reports a direct stake, the underlying investment strategies and holdings by its subsidiaries are stated to remain consistent. This type of internal realignment for reporting purposes is not uncommon for large, complex asset managers.

Stakeholder Impact

• Shareholders: May initially perceive the 0% reported stake by The Vanguard Group as a negative, but understanding the nuance of disaggregated reporting clarifies that underlying Vanguard funds may still hold shares.
• Investment Professionals: Will need to track beneficial ownership from Vanguard's subsidiaries separately to get a complete picture of Vanguard's overall exposure to Voyager Therapeutics Inc.

Key Dates

Recommendation

The filing primarily details an administrative change in how The Vanguard Group reports its beneficial ownership due to an internal realignment. It does not indicate a change in the underlying investment thesis or a divestment by Vanguard's funds. Therefore, it provides no new fundamental information to warrant a change in investment recommendation for Voyager Therapeutics Inc. A 'hold' recommendation is appropriate as existing investment theses remain unchanged based on this filing.

Keywords

Voyager Therapeutics, Vanguard Group, Schedule 13G, Beneficial Ownership, SEC Filing, Institutional Investor, Internal Realignment, Common Stock